Hansa Biopharma Q2 FY26 operating loss widens to SEK 174.1 million; revenue slips to SEK 48.1 million

Reuters2026/07/22 05:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hansa Biopharma posted Q2 revenue of SEK 48.1 million; operating loss widened to SEK 174.1 million.
Net loss widened to SEK 260.5 million; EPS improved to SEK -2.56.
Idefirix product sales eased to SEK 46.8 million; cash and short-term investments rose to SEK 552.8 million.
H1 revenue fell to SEK 82.7 million; net cash from operations swung to SEK 250.5 million.
Signed a €115 million out-licensing deal with SERB for Idefirix in Europe and MENA; received €110 million upfront in early July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260721:BIT:0801:0) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hansa Biopharma Q2 FY26 operating loss widens to SEK 174.1 million; revenue slips to SEK 48.1 million

You may also like

Crypto prices